{"data":[{"accessionNo":"0000921895-26-001391","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":"35104E100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":5346519,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-001391","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":"35104E100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":5346519,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-001391","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":"35104E100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":5346519,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0001346824-26-000143","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001650648","issuerName":"4D MOLECULAR THERAPEUTICS, INC.","ticker":"FDMT","cusip":"35104E100","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Rajeev Shah","reportingCik":null,"personType":"HC,IN","sharesOwned":5105622,"percentOfClass":9.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0001346824-26-000143","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001650648","issuerName":"4D MOLECULAR THERAPEUTICS, INC.","ticker":"FDMT","cusip":"35104E100","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Peter Kolchinsky","reportingCik":null,"personType":"HC,IN","sharesOwned":5105622,"percentOfClass":9.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0001346824-26-000143","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001650648","issuerName":"4D MOLECULAR THERAPEUTICS, INC.","ticker":"FDMT","cusip":"35104E100","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"RA Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":5105622,"percentOfClass":9.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0001346824-26-000143","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001650648","issuerName":"4D MOLECULAR THERAPEUTICS, INC.","ticker":"FDMT","cusip":"35104E100","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"RA Capital Healthcare Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":5105622,"percentOfClass":9.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-001391","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":"35104E100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":5000618,"percentOfClass":9.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-001391","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":"35104E100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":3907517,"percentOfClass":7.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-001391","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":"35104E100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":3907517,"percentOfClass":7.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-001391","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":"35104E100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1093101,"percentOfClass":2.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-001391","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":"35104E100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":1093101,"percentOfClass":2.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-001391","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":"35104E100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":289025,"percentOfClass":0.6,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-001391","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":"35104E100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":289025,"percentOfClass":0.6,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000093751-26-000197","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001650648","issuerName":"4D MOLECULAR THERAPEUTICS INC","ticker":"FDMT","cusip":"35104E100","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":2707875,"percentOfClass":5.3,"filedAt":"2026-05-12","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0001274173-26-000102","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001650648","issuerName":"4D MOLECULAR THERAPEUTICS, INC.","ticker":"FDMT","cusip":"35104E100","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"HC","sharesOwned":5247151,"percentOfClass":10.3,"filedAt":"2026-04-07","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000102909-26-000363","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics Inc","ticker":"FDMT","cusip":"35104E100","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-26","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-000459","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BVF PARTNERS L P/IL","reportingCik":null,"personType":"IA,PN","sharesOwned":5847281,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-000459","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"LAMPERT MARK N","reportingCik":null,"personType":"IN","sharesOwned":5847281,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-000459","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BVF INC/IL","reportingCik":null,"personType":"CO","sharesOwned":5847281,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0001346824-26-000029","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001650648","issuerName":"4D MOLECULAR THERAPEUTICS, INC.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Peter Kolchinsky","reportingCik":null,"personType":"HC,IN","sharesOwned":5713852,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0001346824-26-000029","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001650648","issuerName":"4D MOLECULAR THERAPEUTICS, INC.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"RA Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":5713852,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0001346824-26-000029","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001650648","issuerName":"4D MOLECULAR THERAPEUTICS, INC.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"RA Capital Healthcare Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":5713852,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0001346824-26-000029","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001650648","issuerName":"4D MOLECULAR THERAPEUTICS, INC.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Rajeev Shah","reportingCik":null,"personType":"HC,IN","sharesOwned":5713852,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-000459","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BVF GP HOLDINGS LLC","reportingCik":null,"personType":"OO","sharesOwned":5385980,"percentOfClass":9.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0001274173-26-000069","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001650648","issuerName":"4D MOLECULAR THERAPEUTICS, INC.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"HC","sharesOwned":4635875,"percentOfClass":8.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0001388325-26-000011","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001650648","issuerName":"4D MOLECULAR THERAPEUTICS, INC.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Novo Holdings A/S","reportingCik":null,"personType":"CO","sharesOwned":3650737,"percentOfClass":6.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-000459","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND L P","reportingCik":null,"personType":"PN","sharesOwned":3584039,"percentOfClass":6.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-000459","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BVF I GP LLC","reportingCik":null,"personType":"OO","sharesOwned":3584039,"percentOfClass":6.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-000459","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BIOTECHNOLOGY VALUE FUND II LP","reportingCik":null,"personType":"PN","sharesOwned":1801941,"percentOfClass":3.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-000459","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BVF II GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1801941,"percentOfClass":3.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-000459","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BVF Partners OS Ltd.","reportingCik":null,"personType":"CO","sharesOwned":378475,"percentOfClass":0.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000921895-26-000459","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Biotechnology Value Trading Fund OS LP","reportingCik":null,"personType":"PN","sharesOwned":378475,"percentOfClass":0.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000886982-26-000038","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001650648","issuerName":"4D MOLECULAR THERAPEUTICS, INC.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"THE GOLDMAN SACHS GROUP, INC.","reportingCik":null,"personType":"HC,CO","sharesOwned":4286077.48,"percentOfClass":7.5,"filedAt":"2026-02-09","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0000886982-26-000038","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001650648","issuerName":"4D MOLECULAR THERAPEUTICS, INC.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"GOLDMAN SACHS & CO. LLC","reportingCik":null,"personType":"BD,OO,IA","sharesOwned":4286077.48,"percentOfClass":7.5,"filedAt":"2026-02-09","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0001388325-25-000011","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001650648","issuerName":"4D MOLECULAR THERAPEUTICS, INC.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-13","reportingPerson":"Novo Holdings A/S","reportingCik":null,"personType":"CO","sharesOwned":3175000,"percentOfClass":6.8,"filedAt":"2025-10-20","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"},{"accessionNo":"0002012383-25-002576","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001650648","issuerName":"4D Molecular Therapeutics, Inc.","ticker":"FDMT","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":3062596,"percentOfClass":6.6,"filedAt":"2025-10-17","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt"}],"updatedAt":"2026-11-03T18:38:16.217Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/fdmt","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}